https://ir.ymlib.yonsei.ac.kr/handle/22282913/168850 2026-04-20T10:36:02Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/211443 Title: Interplay of age-sensitive cortical vulnerability and dopaminergic degeneration in clinical manifestations of Parkinson's disease Authors: Kang, Sungwoo; Na, Han Kyu; Yoon, So Hoon; Kim, Han-Kyeol; Ryu, Young Hoon; Lee, Hye Sun; Yoo, Han Soo; Lyoo, Chul Hyoung; 유한수 Abstract: To identify the pattern of cortical atrophy variation in Parkinson's disease (PD) and its contribution to clinical manifestations beyond dopaminergic dysfunction, 45 healthy controls (HCs) underwent MRI, and 222 participants with PD additionally underwent dopamine transporter (DAT)-PET, Unified PD Rating Scale (UPDRS), and neuropsychological tests. Using principal component analysis in PD, a single pattern in cortical thickness (PC1PD) was identified. Linear regressions models were applied to investigate the effects of PC1PD and putaminal DAT (DAT-P) on parkinsonism, and PC1PD and caudate DAT (DAT-C) on cognition. PC1PD accounted for more than 80% of total cortical variance and showed a strong negative correlation with age. The spatial pattern of PC1PD was similar to that of PC1 derived from HCs, but its age-related association was more pronounced in PD. Independent of DAT-P, lower PC1PD was associated with higher UPDRS motor score and showed a synergistic significant interaction with DAT-P on the axial subscore. Independent of DAT-C, lower PC1PD was associated with worse performance in global cognition, language, and executive functions, with synergistic interaction with DATC on global cognition and executive function. The associations of PC1PD with UPDRS motor scores, general cognition, and executive function were stronger in older participants, indicating that aging amplifies the clinical effect of PC1PD. PC1PD represents an age-sensitive cortical vulnerability axis whose expression is amplified in PD, and its interplay with dopaminergic depletion and aging contributes to axial motor symptoms and executive dysfunction in PD. 2026-07-01T00:00:00Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/211618 Title: Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea Authors: Kim, Su-Hyun; Lee, Eun-Jae; Lim, Young-Min; Kim, Hyunjin; Min, Ju-Hong; Choo, Seung Ho; Kim, Byoung Joon; Kim, Sung-Min; Ohn, Dong Seok; Shin, Ha Young; Kim, Ki Hoon; Kwon, Young Nam; Kim, Seung Woo; Kim, Jun-Soon; Kim, Woojun; Sohn, Eunhee; Kim, Sooyoung; Seok, Jin Myoung; Nam, Tai-Seung; Kang, You-Ri; Park, Minsu; Shin, Kyong Jin; Kim, Byung-Jo; Baek, Seol-Hee; Park, Jin-Woo; Oh, Sun-Young; Park, Young Eun; Hong, Yoon-Ho; Ahn, Suk-Won; Ju, Woohee; Oh, Jeeyoung; Lee, Hye Lim; Lee, Tae-Kyeong; Jeon, Byeong-Jun; Kim, Nam-Hee; Kim, Sunyoung; Kwon, Soonwook; Yoon, Byeol-A; Kim, Jong Kuk; Park, Jinseok; Bong, Jeong Bin; Cho, Eun Bin; Kim, Yoo Hwan; Bae, Jong Seok; Oh, Seong-il; Sung Sang, Yoon; Yang, Jiwon; Kim, Do-Hyung; Kim, Jee-Eun; Kim, Juhyeon; Shin, Hyun-June; Kwon, Ohyun; Kim, Ahwon; Kang, Sa-Yoon; Seok, Jung Im; Kang, Minsung; Sung, Joo Hye; Seok, Hung Youl; Shin, Jin-Hong; Choi, Jae-Hwan; Kim, Dae-Seong; Min, Je Hong; Joo, In Soo; So, Jungmin; Hyun, Jae-Won; Kim, Ho Jin Abstract: ObjectivesTo provide the clinically validated, nationwide estimates of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in Korea, and to describe their relative proportions.MethodsFrom January to March 2025, 47 referral hospitals participating in a nationwide hospital-based registry identified actively followed patients with MS, NMOSD, or MOGAD. Diagnoses followed international criteria, and antibody status was confirmed using validated CBAs. Actively followed patients had >= 1 outpatient visit in the prior 6 months. Centers provided demographics, treatments, and Expanded Disability Status Scale. Prevalence used national population data.ResultsA total of 4,196 patients were identified, 1,799 MS, 1,616 NMOSD, and 781 MOGAD (ratio 2.3:2.1:1). Mean age at onset was 33.4 +/- 12.0 years for MS, 42.7 +/- 14.7 for NMOSD, and 41.7 +/- 17.8 for MOGAD, and the female-to-male ratios were 2.2:1 for MS, 5.1:1 for NMOSD (6.5:1 in aquaporin-4-IgG positive cases), and 1.5:1 for MOGAD. Crude prevalence estimates were 3.48, 3.13, and 1.51 per 100,000, respectively.DiscussionThis nationwide registry demonstrates a distinctive Korean CNS inflammatory demyelinating disease profile, with a relatively higher proportion of NMOSD and MOGAD reflecting the low prevalence of MS in East Asia. 2026-04-01T00:00:00Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/210339 Title: Progression Independent of Relapse Activity in Aquaporin-4-IgG-Positive NMOSD Authors: Kang, You-Ri; Kim, Ki Hoon; Hyun, Jae-Won; Kim, Su-Hyun; Kim, Ho Jin Abstract: ObjectivesDisability in neuromyelitis optica spectrum disorder (NMOSD) is traditionally considered relapse-driven, but recent studies have suggested possible subclinical progression. Whether this translates into clinically meaningful disability worsening remains unclear, and quantitative data on progression independent of relapse activity (PIRA) in NMOSD are limited. We investigated the frequency and clinical relevance of PIRA in a large cohort with long-term follow-up.MethodsWe retrospectively analyzed 281 patients with AQP4-IgG-positive NMOSD with >= 2 years of follow-up. Significant Expanded Disability Status Scale (EDSS) worsening occurred following conventional thresholds, using a roving baseline. PIRA was defined as EDSS worsening without relapse between assessments, confirmed >= 6 months later, sustained, and not attributable to confounders. Relapse-associated worsening (RAW) was defined when the best EDSS score assessed >= 6 months after relapse still met the threshold.ResultsThe mean follow-up duration was 11.3 +/- 5.1 years, and the mean relapse-free duration was 8.3 +/- 5.2 years. A total of 1,662 EDSS assessments were performed, with a median of 5 per patient (interquartile range, 4-7). Seven patients (2.5%) met PIRA criteria. Despite no treatment escalation, none worsened further. Among 194 patients with relapses, 70 (36.1%) experienced RAW.DiscussionPIRA was rare, even with extended observation using a formal framework, reaffirming relapse as the principal driver of disability and supporting continued focus on relapse prevention. 2026-03-01T00:00:00Z https://ir.ymlib.yonsei.ac.kr/handle/22282913/211246 Title: Sex differences in the association between chronotype and anxiety: A nationwide population study Authors: Yum, Jungyon; Cho, Soomi; Ha, Woo-seok; Kim, Kyung Min; Lee, Wonwoo; Chu, Min Kyung Abstract: Backgrounds: This study aimed to investigate potential sex differences in the association between anxiety and chronotype. Methods: Nationwide population-based data were analyzed from 2838 individuals aged 20-59 years who participated in the Circannual Change in Headache and Sleep Study. The chronotype was scored using the Morningness-Eveningness Questionnaire, and anxiety levels were assessed using the Generalized Anxiety Disorder-7 scale. Covariates included sociodemographic factors, depression, employment status, alcohol consumption, current smoker, body mass index, insomnia severity, and average sleep duration. Results: In this cohort (mean age = 40.5 +/- 11.1 years, 1424 women [50.2 %]. 1414 men [49.8 %]), anxiety was more commonly reported by women (12.2 %) than men (7.4 %), with the evening chronotype group showing the highest anxiety prevalence (15.3 %). After adjusting for covariates, men with a morning chronotype showed a significantly lower risk of anxiety than did those with an intermediate chronotype, however, no significant difference in anxiety risk was observed for evening-type men. Among women, chronotype was not significantly associated with anxiety. Conclusions: Differences in the chronotype-anxiety association were observed between men and women. Specifically, having a morning chronotype may reduce the risk of anxiety in men, whereas this protective effect was not observed in women. These findings suggest the need for sex-specific chronotype-targeted approaches for the prevention and management of anxiety. 2026-03-01T00:00:00Z